Sold as Letybo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Letibotulinumtoxina-Wlbg (sold as Letybo), first approved Feb 29, 2024, with 0 new uses approved and 2 published complete response letters.
| Apr 12, 2023 | LetibotulinumtoxinAFacility Inspections, Product Quality, Microbiology | Approved |
| Mar 31, 2022 | LetibotulinumtoxinA | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA